XenoPort, Inc. (XNPT)
A biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.
Recs
Negative Earnings Surprise
Recs
2/09/2010
Recs
from article in Morn* 9/17/09
announced positive results Thursday from a Phase IIb clinical trial for XP13512 for neuropathic pain associated with post-herpetic neuralgia. The drug candidate was successful in demonstrating statistically significant results over placebo at all dosing levels, and we plan to slightly raise our fair value estimate in the wake of this news. The 14-week, double-blind trial evaluated the safety and efficacy of XP13512 and had a total enrollment of 375 subjects with PHN who experienced pain following the healing of the herpes zoster (shingles) skin rash for at least three months. XP13512 was statistically significan t on the primary endpoint of the trial, which was improvement from baseline in the 24-hour average pain intensity score. We think this is great news for XenoPort, which experienced a setback with XP13512 in April, when the drug failed a Phase II study for pain associated with diabetes. XenoPort has partnered with GlaxoSmithKline GSK on the drug, which is still on track for final approval from the Food and Drug Administration for restless leg syndrome, having met all primary goals in its Phase III trials.
Recs
This is a winner. FDA had some formating issues with Solzira data. Eventually this drug will pass. Target 55
Recs
Purely a value play. Doesn't deserve a 13% drop because Solzira's NDA has to be reformatted.
Recs
http://www.fool.com/investing/small-cap/2008/01/16/stocks-on-bubble-watch.aspx
Recs
Valuable potential medical technology for a variety of common clinical problems.
Recs
As of close of business on 12/04/2007, this was a 1-star Morningstar stock that was trading at more than double it's Morningstar fair value.
Recs
Xenoport's drug delivery technology shows great promise given its pairing with GSK's restless leg syndrome drug and their recent partnership agreement expected to bring in cashflows north of $600M upon hitting milestones....Right now in Phase III clinical trials...Most importantly this companies drug delivery technology can be paired with various drugs on the market giving it ultimately a great platform to build a solid business upon....
Recs
Rare non binary biotech. Pro-drug transporter works, pipeline good -RLS/GERD/Migraine/Parkinsons. May get taken out by big pharma or become big pharma. Each way bet.
Recs
They have a product in phase III trials. Stock will keep going up until product goes kapluuie or executives start buying castles. Pull out of this one if there is a negative report on the product!
Recs
This company has a strong product candidate in XP512 for the treatment of restless legs syndrome that is different in mechanism of action from all the other RLS treatments on the market.
Recs
52 week high soon

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 13 of 13